Drugs Made In America Acquisition Corp. Rights
Drugs Made In America Acquisition Corp. Rights
Your view on DMAAR
Overview
What the company does, where it operates, and who runs it.
About Drugs Made In America Acquisition Corp. Rights
- Industry
- Shell Companies
- Sector
- Financial Services
- CEO
- Roger Bendelac
- Headquarters
- 1 East Broward Blvd Suite 700, New York, NY, US
- Industry
- Shell Companies
- Sector
- Financial Services
- CEO
- Roger Bendelac
- Headquarters
- 1 East Broward Blvd Suite 700, New York, NY, US
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company (SPAC), established with the primary objective of identifying and acquiring one or more active businesses or their assets.
The company plans to achieve these acquisitions through various transactional structures, including mergers, exchanges of equity shares, direct asset purchases, stock acquisitions, or broader corporate reorganizations.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Drugs Made In America Acquisition Corp. Rights from FRC's valuation model, read against the market price. DMAAR last traded at $0.11, 55.5× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Drugs Made In America Acquisition Corp. Rights. Starting points for Drugs Made In America Acquisition Corp. Rights: P/E 55.5, EPS $0.30, beta 4.04 — an Shell Companies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Drugs Made In America Acquisition Corp. Rights. Drugs Made In America Acquisition Corp. Rights does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Drugs Made In America Acquisition Corp. Rights. Trailing twelve-month EPS for Drugs Made In America Acquisition Corp. Rights stands at $0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Drugs Made In America Acquisition Corp. Rights. Drugs Made In America Acquisition Corp. Rights has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
More Shell Companies companies
Market cap
- PMTRUPerimeter Acquisition Corp. INASDAQ$260M
- PMTRWPerimeter Acquisition Corp. I WarrantNASDAQ$9M
- POLEAndretti Acquisition Corp. IINASDAQ$148M
- POLEUAndretti Acquisition Corp. IINASDAQ$315M
- POLEWAndretti Acquisition Corp. IINASDAQ$203M
- PONORPono Capital Four, Inc. RightsNASDAQ$11M
- PPYAPapaya Growth Opportunity Corp. IOTC$98M
- PPYAUPapaya Growth Opportunity Corp. IOTC
- PSCOProtoSource CorporationOTC$8M
- PTACPatriot Acquisition Corp.NASDAQ$176M
- PTACUPatriot Acquisition Corp.NASDAQ$223M
- PTORPraetorian Acquisition Corp.NASDAQ$254M
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Drugs Made In America Acquisition Corp. Rights executives and directors. Shares of Drugs Made In America Acquisition Corp. Rights have traded between $0.15 and $0.15 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Drugs Made In America Acquisition Corp. Rights. Coverage tracks Drugs Made In America Acquisition Corp. Rights within Shell Companies (Financial Services). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Drugs Made In America Acquisition Corp. Rights.